Sutro Biopharma (STRO) Equity Ratio (2017 - 2025)

Sutro Biopharma has disclosed Equity Ratio across 9 years of filings, most recently posting 0.76 for Q4 2025.

• Equity Ratio for Q4 2025 came in at 0.76, down 761.5% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.76 (down 761.5% YoY), and the FY2025 annual result was 0.76, down 761.5% from the prior year.
• Equity Ratio came in at 0.76 for Q4 2025 at Sutro Biopharma, down from 0.42 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.86 in Q1 2021 to a low of 0.76 in Q4 2025.
• The 5-year median for Equity Ratio is 0.33 (2023), against an average of 0.33.
• Across the five-year window, Equity Ratio soared 60.69% in 2021 and sank 761.5% in 2025, its largest moves.
• Sutro Biopharma's Equity Ratio stood at 0.74 in 2021, then dropped by 27.9% to 0.53 in 2022, then tumbled by 40.4% to 0.32 in 2023, then sank by 63.77% to 0.12 in 2024, then tumbled by 761.5% to 0.76 in 2025.
• The last three Equity Ratio figures came in at 0.76 (Q4 2025), 0.42 (Q3 2025), and 0.12 (Q2 2025), per Business Quant data.